目的:探讨下调磷酸核糖焦磷酸合成酶亚基II(PRPS2)基因表达对人结肠癌HCT116细胞增殖和凋亡的影响。方法:构建PRPS2基因干扰载体sh-PRPS2,正常对照组不转染载体,阴性对照组转染阴性对照载体sh-PRPS2-0,3个实验组分别转染干扰载体sh-PRPS...目的:探讨下调磷酸核糖焦磷酸合成酶亚基II(PRPS2)基因表达对人结肠癌HCT116细胞增殖和凋亡的影响。方法:构建PRPS2基因干扰载体sh-PRPS2,正常对照组不转染载体,阴性对照组转染阴性对照载体sh-PRPS2-0,3个实验组分别转染干扰载体sh-PRPS2-1、sh-PRPS2-2和sh-PRPS2-3,经DNA测序鉴定后转染人结肠癌HCT116细胞,分别采用RT-PCR和Western blot法检测各载体转染后细胞PRPS2 m RNA和蛋白水平的表达变化,CCK8试剂盒检测细胞增殖能力,流式细胞术检测细胞周期及凋亡的变化。结果:经DNA测序证实成功构建sh-PRPS2干扰载体3个,分别为sh-PRPS2-1、sh-PRPS2-2和sh-PRPS2-3。将上述3个干扰载体分别转染HCT116细胞72 h后,RT-PCR结果显示,PRPS2 m RNA相对表达量依次为0.61±0.03、0.89±0.02、0.27±0.05,与对照组比较,均显著下降(P<0.05)。Western blot结果显示,PRPS2蛋白相对表达量依次为0.37±0.06、0.84±0.05、0.30±0.04,与对照组比较均显著下降(P<0.05)。转染sh-PRPS2-3载体72 h后细胞增殖抑制率达19.8%±2.4%,凋亡率上升至68.4%±4.6%,G0/G1期细胞比例上升为12.9%±3.8%。结论:PRPS2的低表达可以有效抑制细胞增殖,促进细胞凋亡,细胞阻滞于G0/G1期,本研究为肿瘤的靶向治疗提供了研究基础。展开更多
Tumor relapse is the major cause of treatment failure in childhood acute lymphoblastic leukemia(ALL),yet the underlying mechanisms are still elusive.Here,we demonstrate that phosphoribosyl pyrophosphate synthetase 2(P...Tumor relapse is the major cause of treatment failure in childhood acute lymphoblastic leukemia(ALL),yet the underlying mechanisms are still elusive.Here,we demonstrate that phosphoribosyl pyrophosphate synthetase 2(PRPS2)mutations drive ALL relapse through influencing PRPS1/2 hexamer stability.Ultra-deep sequencing was performed to identify PRPS2 mutations in ALL samples.The effects of PRPS2 mutations on cell survival,cell apoptosis,and drug resistance were evaluated.In vitro PRPS2 enzyme activity and ADP/GDP feedback inhibition of PRPS enzyme activity were assessed.Purine metabolites were analyzed by ultra-performance liquid-chromatography tandem mass spectrometry(UPLC–MS/MS).Integrating sequencing data with clinical information,we identified PRPS2 mutations only in relapsed childhood ALL with thiopurine therapy.Functional PRPS2 mutations mediated purine metabolism specifically on thiopurine treatment by influencing PRPS1/2 hexamer stability,leading to reduced nucleotide feedback inhibition of PRPS activity and enhanced thiopurine resistance.The 3-amino acid V103-G104-E105,the key difference between PRPS1 and PRPS2,insertion in PRPS2 caused severe steric clash to the interface of PRPS hexamer,leading to its low enzyme activity.In addition,we demonstrated that PRPS2 P173R increased thiopurine resistance in xenograft models.Our work describes a novel mechanism by which PRPS2 mutants drive childhood ALL relapse and highlights PRPS2 mutations as biomarkers for relapsed childhood ALL.展开更多
文摘目的:探讨下调磷酸核糖焦磷酸合成酶亚基II(PRPS2)基因表达对人结肠癌HCT116细胞增殖和凋亡的影响。方法:构建PRPS2基因干扰载体sh-PRPS2,正常对照组不转染载体,阴性对照组转染阴性对照载体sh-PRPS2-0,3个实验组分别转染干扰载体sh-PRPS2-1、sh-PRPS2-2和sh-PRPS2-3,经DNA测序鉴定后转染人结肠癌HCT116细胞,分别采用RT-PCR和Western blot法检测各载体转染后细胞PRPS2 m RNA和蛋白水平的表达变化,CCK8试剂盒检测细胞增殖能力,流式细胞术检测细胞周期及凋亡的变化。结果:经DNA测序证实成功构建sh-PRPS2干扰载体3个,分别为sh-PRPS2-1、sh-PRPS2-2和sh-PRPS2-3。将上述3个干扰载体分别转染HCT116细胞72 h后,RT-PCR结果显示,PRPS2 m RNA相对表达量依次为0.61±0.03、0.89±0.02、0.27±0.05,与对照组比较,均显著下降(P<0.05)。Western blot结果显示,PRPS2蛋白相对表达量依次为0.37±0.06、0.84±0.05、0.30±0.04,与对照组比较均显著下降(P<0.05)。转染sh-PRPS2-3载体72 h后细胞增殖抑制率达19.8%±2.4%,凋亡率上升至68.4%±4.6%,G0/G1期细胞比例上升为12.9%±3.8%。结论:PRPS2的低表达可以有效抑制细胞增殖,促进细胞凋亡,细胞阻滞于G0/G1期,本研究为肿瘤的靶向治疗提供了研究基础。
基金National Natural Science Foundation of China(81972341,81900158,81772663,81874078,82072896)Shanghai Municipal Science and Technology Commission(201409002700,19JC1413500,21XD1403100)+1 种基金Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support(20161310)Pudong New Area Science&Technology Development Fund(PKJ2018-Y47).
文摘Tumor relapse is the major cause of treatment failure in childhood acute lymphoblastic leukemia(ALL),yet the underlying mechanisms are still elusive.Here,we demonstrate that phosphoribosyl pyrophosphate synthetase 2(PRPS2)mutations drive ALL relapse through influencing PRPS1/2 hexamer stability.Ultra-deep sequencing was performed to identify PRPS2 mutations in ALL samples.The effects of PRPS2 mutations on cell survival,cell apoptosis,and drug resistance were evaluated.In vitro PRPS2 enzyme activity and ADP/GDP feedback inhibition of PRPS enzyme activity were assessed.Purine metabolites were analyzed by ultra-performance liquid-chromatography tandem mass spectrometry(UPLC–MS/MS).Integrating sequencing data with clinical information,we identified PRPS2 mutations only in relapsed childhood ALL with thiopurine therapy.Functional PRPS2 mutations mediated purine metabolism specifically on thiopurine treatment by influencing PRPS1/2 hexamer stability,leading to reduced nucleotide feedback inhibition of PRPS activity and enhanced thiopurine resistance.The 3-amino acid V103-G104-E105,the key difference between PRPS1 and PRPS2,insertion in PRPS2 caused severe steric clash to the interface of PRPS hexamer,leading to its low enzyme activity.In addition,we demonstrated that PRPS2 P173R increased thiopurine resistance in xenograft models.Our work describes a novel mechanism by which PRPS2 mutants drive childhood ALL relapse and highlights PRPS2 mutations as biomarkers for relapsed childhood ALL.